CRIS Current Research Information System

ROCCHI, SERENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.473
NA - Nord America 2.267
EU - Europa 1.704
AF - Africa 174
SA - Sud America 161
OC - Oceania 9
Totale 7.788
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.221
VN - Vietnam 1.160
CN - Cina 874
SG - Singapore 763
IT - Italia 507
GB - Regno Unito 240
DE - Germania 201
HK - Hong Kong 190
SE - Svezia 155
KR - Corea 144
IN - India 118
BR - Brasile 113
FR - Francia 102
NL - Olanda 99
FI - Finlandia 77
CI - Costa d'Avorio 72
RU - Federazione Russa 69
IE - Irlanda 66
JP - Giappone 47
ZA - Sudafrica 32
UA - Ucraina 30
PH - Filippine 29
SC - Seychelles 28
BG - Bulgaria 27
CA - Canada 26
TG - Togo 25
AT - Austria 23
BD - Bangladesh 22
AR - Argentina 20
MX - Messico 18
BE - Belgio 17
ES - Italia 17
ID - Indonesia 17
EE - Estonia 16
PL - Polonia 16
TH - Thailandia 15
CH - Svizzera 14
TW - Taiwan 14
JO - Giordania 12
IQ - Iraq 11
TR - Turchia 10
EC - Ecuador 8
AU - Australia 7
NG - Nigeria 7
SA - Arabia Saudita 7
IR - Iran 5
LT - Lituania 5
CO - Colombia 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
MY - Malesia 4
PK - Pakistan 4
PT - Portogallo 4
PY - Paraguay 4
RO - Romania 4
UZ - Uzbekistan 4
CL - Cile 3
LB - Libano 3
OM - Oman 3
PE - Perù 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
CY - Cipro 2
HU - Ungheria 2
IL - Israele 2
KE - Kenya 2
KZ - Kazakistan 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
VE - Venezuela 2
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
MT - Malta 1
NP - Nepal 1
PS - Palestinian Territory 1
SI - Slovenia 1
SV - El Salvador 1
TN - Tunisia 1
ZM - Zambia 1
Totale 7.788
Salva come PNG Salva come JPEG
Città #
Singapore 548
Ashburn 321
Hefei 312
Ho Chi Minh City 305
Hanoi 243
Chandler 220
Hong Kong 185
Southend 175
Fairfield 158
Bologna 143
Seoul 141
San Jose 110
Beijing 84
Woodbridge 80
Ann Arbor 75
Abidjan 72
Wilmington 71
Dublin 66
Seattle 66
Dong Ket 64
Houston 63
Helsinki 59
Santa Clara 58
Cambridge 51
Los Angeles 50
Haiphong 47
New York 47
Boardman 46
Dallas 45
Princeton 44
Council Bluffs 38
Tokyo 37
Lauterbourg 36
Milan 34
Munich 31
Hyderabad 30
Bengaluru 26
Sofia 26
Lomé 25
Da Nang 24
Frankfurt am Main 24
Turin 23
Bremen 22
Fabriano 18
Guangzhou 18
Redondo Beach 18
São Paulo 18
Biên Hòa 17
Redmond 17
Buffalo 16
Florence 16
Jinan 16
Westminster 16
Brussels 15
Can Tho 15
Ha Long 15
San Diego 15
Berlin 14
Hải Dương 14
Nuremberg 14
Padova 14
Quận Bình Thạnh 14
Shanghai 14
Vienna 14
Falkenstein 13
London 13
Thái Nguyên 13
Amman 12
Jacksonville 12
Jakarta 12
Nanjing 12
Amsterdam 11
Bern 11
Rome 11
Tongling 11
Warsaw 11
Chicago 10
Lappeenranta 10
Zhengzhou 10
Điện Bàn 10
Dhaka 9
Nanchang 9
Ninh Bình 9
Quận Một 9
Redwood City 9
Shenyang 9
Brooklyn 8
Bến Tre 8
Changsha 8
Paris 8
Tianjin 8
Toronto 8
Turku 8
Wuhan 8
Abeokuta 7
Atlanta 7
Bắc Giang 7
Falls Church 7
Johannesburg 7
Saint Petersburg 7
Totale 4.995
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 706
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 338
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 265
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 249
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 246
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 232
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 220
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 211
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 207
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 204
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 203
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 202
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 200
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 197
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 197
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 194
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 185
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 181
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 179
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 175
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 175
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 172
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 169
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 168
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project 154
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 147
Novel insights and therapeutic approaches in secondary AML 144
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy 143
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 143
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 143
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 134
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma 130
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 130
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 127
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors 121
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype 120
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 119
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 104
null 98
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 97
Which is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome? 94
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight 90
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 86
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 81
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 74
Totale 7.954
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.834
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.834
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021161 0 0 0 0 0 0 0 0 0 12 20 129
2021/2022603 63 29 28 58 41 20 17 41 26 74 101 105
2022/2023845 64 105 32 136 57 76 28 45 134 30 87 51
2023/2024395 23 41 25 35 23 90 10 73 6 22 34 13
2024/20251.377 90 135 120 125 110 62 110 40 36 140 144 265
2025/20263.621 435 856 293 330 304 159 310 86 645 203 0 0
Totale 7.954